Asset Details
Do you wish to reserve the book?
Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types
Do you wish to request the book?
Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Statistical Methods for Assessing Differential Vaccine Protection Against Human Immunodeficiency Virus Types
1998
Overview
The human immunodeficiency virus type 1 (HIV-1) is extremely diverse. In assessing the utility of an HIV-1 vaccine, an important issue is the possibility of differential protection. We discuss statistical methods of inferring how the vaccine efficacy may vary with viral type from data that would be collected from a randomized, double-blind, placebo-controlled preventive vaccine efficacy trial. Detailed characterization of virus isolated from individuals infected during the trial will be available. We focus on the highly simplified case in which the viral characteristics are summarized by a single feature, which may be nominal, or a scalar quantity that represents distance between the isolate and the prototype virus or viruses used in the vaccine preparation. We consider discrete categorical and continuous response models for this quantity and identify models whose parameters can be interpreted as log ratios of strain-specific relative risks of infection in a prospective model for HIV-1 exposure and transmission. Methods of inference are described for the multinomial logistic regression (MLR) model for discrete categorical response, and a new semiparametric model which can be viewed as a continuous analog of the MLR model is introduced. The methods are illustrated by application to HIV-1 and hepatitis B vaccine trial data.
Publisher
International Biometric Society
Subject
/ Clinical Trials, Phase III as Topic - statistics & numerical data
/ Hepatitis B Vaccines - pharmacology
/ HIV
/ HIV 1
/ HIV Infections - prevention & control
/ HIV-1 - isolation & purification
/ Humans
/ Male
/ Modeling
/ Placebos
/ Randomized Controlled Trials as Topic - statistics & numerical data
/ Ratios
/ Viruses
